Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19IL2 and L19TNF in Stage III/IV M1a Melanoma
NCT02076633Phase 2Completed
- Sponsor
- Philogen
- Start
- Dec 2012
- Primary completion
- May 2015
- Modality
- Antibody Fragments, Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of darleukin, onfekafusp alfa in Malignant Melanoma (MM), sponsored by Philogen. Started Dec 2012; status: completed.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02076633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076633.